Acadia Pharmaceuticals ACAD Stock Based Compensation Capitalized
Stock Based Compensation Capitalized at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept acad:StockBasedCompensationCapitalized.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's stock based compensation capitalized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Acadia Pharmaceuticals's stock based compensation capitalized?
- Acadia Pharmaceuticals (ACAD) reported stock based compensation capitalized of $118K in Q1 2026.
- How has Acadia Pharmaceuticals's stock based compensation capitalized changed year-over-year?
- Acadia Pharmaceuticals's stock based compensation capitalized increased by 25.5% year-over-year, from $94K to $118K.
- What does stock based compensation capitalized mean?
- This represents the portion of stock-based compensation expense that is capitalized into the cost of assets rather than being expensed immediately in the income statement. It reflects the allocation of equity-based rewards to long-term projects or asset development. Understanding this helps investors reconcile total equity compensation with the impact on the balance sheet and future depreciation.